Therefore, we believe that ProGRP is not a tumor marker that is particularly elevated in patients with BM, but it is useful for predicting tumor growth in the brain, a sanctuary to which chemotherapy is difficult to transfer among the select patients who responded well to initial therapy. The gene discussed is GRP; the disease is neoplasm.